Biomerieux (BioFire) See Strong Q3 Growth

October 21, 2021

Biomerieux, which includes US-based BioFire, announced Q3 sales growth at 11.6%, significantly above expectations due, in part, to a strong upturn in US respiratory panels demand.

With this upturn, BioMérieux is raising its FY’21 outlook.

Chairman and CEO, Alexandre Mérieux,, said: “During the third quarter of 2021, we saw an uptake of multiplexing respiratory demand in the US, while all other business lines, namely microbiology, immunoassays and industrial applications, kept on maintaining solid growth. We are therefore raising upward 2021 sales revenue…”

• Organic growth of 12.1% at constant exchange rates and scope of consolidation over the first nine months of the year:
  • €2,452 million in sales
  • Up 8.2% as reported

• Q3 sales organic growth at 11.6%, significantly above expectations due to a strong upturn in US respiratory panels demand, combined with a solid momentum in all other applications
• Upward revision of 2021 outlook: in the light of Q3 higher-than-expected respiratory multiplexing testing demand,  bioMérieux  is raising its FY’21 outlook. Full year  sales  are now expected to grow between 4% and 7% (previously: at neutral to mid-single digit rate), at constant exchange rates and scope of consolidation. Contributive operating income before non-recurring items should be above €700 million (previously: in line with 2020) at current exchange rates.

Alexandre Mérieux, Chairman and Chief Executive Officer, said: “During the third quarter of 2021,  we saw an uptake of multiplexing respiratory demand in the US, while all other business lines, namely microbiology, immunoassays and industrial applications, kept on maintaining solid growth. We are therefore raising upward 2021 sales revenue and contributive operating income outlook. This extraordinary 2021 operating income is however embedding a low level of operating expenses within the pandemic context, and is therefore not projectable as such beyond 2021.”

Download the full report here.